{{Drugbox
| verifiedrevid = 458613328
| IUPAC_name = (''RS'')-4-[(4-chlorophenyl)methyl]-2- (1-methylazepan-4-yl)-phthalazin-1-one
| image = Azelastine.svg
| image2 = Azelastine-3D-balls.png
<!--Clinical data-->
| tradename = Astelin, Optivar, among others.<ref name=Names/>
| Drugs.com = {{drugs.com|monograph|azelastine}}
| MedlinePlus = a603009
| pregnancy_US = C
| legal_AU = S2
| legal_US = Rx Only
| legal_UK = POM
| routes_of_administration = intranasal, ocular
<!--Pharmacokinetic data-->
| bioavailability = 40% (intranasal)
| elimination_half-life = 22 hours
<!--Identifiers-->
| IUPHAR_ligand = 7121
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 58581-89-8
| ATC_prefix = R01
| ATC_suffix = AC03
| ATC_supplemental =  {{ATC|R06|AX19}}, {{ATC|S01|GX07}}
| PubChem = 2267
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00972
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2180
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = ZQI909440X
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07483
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 2950
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 639
<!--Chemical data-->
| C=22 | H=24
| Cl=1 | N=3
| O=1
| molecular_weight = 381.898 g/mol
| smiles = Clc1ccc(cc1)CC\3=N\N(C(=O)c2ccccc2/3)C4CCCN(C)CC4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H24ClN3O/c1-25-13-4-5-18(12-14-25)26-22(27)20-7-3-2-6-19(20)21(24-26)15-16-8-10-17(23)11-9-16/h2-3,6-11,18H,4-5,12-15H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MBUVEWMHONZEQD-UHFFFAOYSA-N
}}
'''Azelastine''' is a potent, second-generation, selective, [[histamine antagonist]] (histamine-H<sub>1</sub>-receptor antagonist) used as a first line therapy of mild intermittent, moderate/severe intermittent and mild persistent [[rhinitis]] (new classification system for rhinitis).{{citation needed|date=June 2017}}

Azelastine has been formulated both as a [[nasal spray]] and as [[eye drops]] and are available worldwide under many brand names.<ref name=Names/>

==Medical uses==
Azelastine nasal spray is indicated for the local treatment of the symptoms of [[seasonal allergic rhinitis]] and [[perennial allergic rhinitis]], such as [[rhinorrhea]], sneezing and nasal [[pruritus]] in adults and children 5 years of age and older.<ref name=AHRQ>AHRQ  [http://www.guidelines.gov/content.aspx?id=24599 Allergic Rhinitis and its Impact on Asthma (ARIA) treatment guidelines]</ref><ref name="Rhinolast Nasal Spray">
{{cite web
| url = http://www.medicines.org.uk/EMC/medicine/9160/SPC/Rhinolast+Nasal+Spray/
| title = Rhinolast Nasal Spray Summary of Product Characteristics
| date = Oct 2009
| accessdate = 2010-04-27
}}</ref><ref name="Astelin FDA Prescribing Information">
{{cite web
| url = http://www.drugs.com/pro/astelin.html| title = Astelin FDA Prescribing Information
| accessdate = 2010-04-27
}}</ref> In some countries, it is also indicated for the treatment of [[vasomotor rhinitis]] in adults and children ≥ 12 years old.<ref name="Astelin FDA Prescribing Information" /> Azelastine eyes drops are indicated for the local treatment of seasonal and perennial [[allergic conjunctivitis]].<ref name="Optilast Eye Drops Summary of Product Characteristics">
{{cite web
| url = http://www.medicines.org.uk/EMC/medicine/9161/SPC/Optilast+Eye+Drops/| title = Optilast Eye Drops Summary of Product Characteristics
| date = Jan 2010
| accessdate = 2010-04-27
}}</ref><ref name="Optivar Eye Drops FDA Prescribing Information">
{{cite web
| url = http://www.drugs.com/pro/optivar.html| title = Optivar Eye Drops FDA Prescribing Information| date = Jan 2010
| accessdate = 2010-04-27
}}</ref>

==Side effects==
Azelastine is safe and well tolerated in both adults and children with [[allergic rhinitis]].<ref>{{cite journal|last1=McNeely|first1=W|last2=Wiseman|first2=LR|title=Intranasal azelastine. A review of its efficacy in the management of allergic rhinitis.|journal=Drugs|date=July 1998|volume=56|issue=1|pages=91–114|pmid=9664202|doi=10.2165/00003495-199856010-00011}}</ref><ref name="Ratner et al, 1994">{{cite journal |vauthors=Ratner PH, Findlay SR, Hampel F, van Bavel J, Widlitz MD, Freitag JJ |title=A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis |journal=The Journal of Allergy and Clinical Immunology |volume=94 |issue=5 |pages=818–25 |date=November 1994 |pmid=7963150 |doi=10.1016/0091-6749(94)90148-1}}</ref><ref name="LaForce et al, 1996">{{cite journal |vauthors=LaForce C, Dockhorn RJ, Prenner BM |title=Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial |journal=Annals of Allergy, Asthma & Immunology |volume=76 |issue=2 |pages=181–8 |date=February 1996 |pmid=8595539 |doi=10.1016/S1081-1206(10)63420-5|display-authors=etal}}</ref> Bitter taste, headache, nasal burning and [[somnolence]] are the most frequently reported adverse events. US prescribing recommendations warn against the concurrent use of alcohol and/or other central nervous system depressants, but to date there have been no studies to assess the effects of azelastine nasal spray on the CNS in humans. More recent studies<ref name="Corren et al, 2005">{{cite journal |vauthors=Corren J, Storms W, Bernstein J, Berger W, Nayak A, Sacks H |title=Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis |journal=Clinical Therapeutics |volume=27 |issue=5 |pages=543–53 |date=May 2005 |pmid=15978303 |doi=10.1016/j.clinthera.2005.04.012}}</ref><ref name="Berger et al, 2006">{{cite journal |vauthors=Berger W, Hampel F, Bernstein J, Shah S, Sacks H, Meltzer EO |title=Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis |journal=Annals of Allergy, Asthma & Immunology |volume=97 |issue=3 |pages=375–81 |date=September 2006 |pmid=17042145 |doi=10.1016/S1081-1206(10)60804-6}}</ref> have shown similar degrees of somnolence (approx. 2%) compared with placebo treatment. The problem of bitter taste may be reduced by correct application of the nasal spray (i.e. slightly tipping the head forward and not inhaling the medication too deeply), or alternatively using the azelastine/sucralose formulation.

==Pharmacokinetics and metabolism==
The systemic [[bioavailability]] of azelastine is approximately 40% when administered intranasally. Maximum plasma concentrations (Cmax) are observed within 2–3 hours. The [[elimination half life]], steady-state [[volume of distribution]] and plasma clearance are 22 h, 14.5 l/kg and 0.5 l/h/kg respectively (based on intravenous and oral administration data). Azelastine is oxidatively metabolized by the [[cytochrome P450]] family into its active metabolite, desmethylazelastine, and two inactive carboxylic acid metabolites. Approximately 75% of an oral dose is excreted in feces. [[Pharmacokinetics]] of orally administered azelastine are not affected by age, gender or hepatic impairment.<ref name="Horak & Zieglmayer, 2009">{{cite journal |doi=10.1586/eci.09.38 |pmid=20477689 |title=Azelastine nasal spray for the treatment of allergic and nonallergic rhinitis |year=2009 |last1=Horak |first1=Friedrich |last2=Zieglmayer |first2=Ursula Petra |journal=Expert Review of Clinical Immunology |volume=5 |issue=6 |pages=659–69}}</ref>

==Mode of action==
Azelastine has a triple mode of action:<ref name="Horak & Zieglmayer, 2009" />
# [[Antihistamine |Anti-histamine]] effect,
# [[Mast_cell_stabilizer|Mast-cell stabilizing]] effect and
# [[Anti-inflammatory]] effect.

==Chemical properties==
The chemical nomenclature of azelastine is (±)-1-(2H)-phthalazinone, 4-[(4-chlorophenyl) methyl]-2-(hexahydro-1-methyl-1H-azepin-4-yl)-monohydrochloride. It is white, almost odorless with a bitter taste.<ref>drugs.com [http://www.drugs.com/pro/azelastine.html Azelastine] Page accessed June 28, 2015</ref>

==Society and culture==

===Availability===
Azelastine is generic and available worldwide under many brand names.<ref name=Names>Drugs.com [http://www.drugs.com/international/azelastine.html Drugs.com international listings for azelastine] Page accessed June 28, 2015</ref>

==References==
{{Reflist|2}}

==External links==
* [http://www.medicines.org.uk/EMC/medicine/9160/SPC/Rhinolast+Nasal+Spray/ Rhinolast Nasal Spray Summary of Product Characteristics]
* [http://www.medicines.org.uk/EMC/medicine/9161/SPC/Optilast+Eye+Drops/ Optilast Eye Drops Summary of Product Characteristics]
* [http://www.whiar.org/Documents&Resources.php#1 Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines]

{{Antihistamines}}
{{Histamine receptor modulators}}
{{Leukotriene signaling modulators}}

[[Category:H1 receptor antagonists]]
[[Category:Azepanes]]
[[Category:Chloroarenes]]
[[Category:Mast cell stabilizers]]
[[Category:Phthalazines]]
[[Category:Lactams]]